Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544684 | 0.83 | SMN1; SMN2 (0.49) | GRIN1GRIN2BCCR3CCR5GAA | |
| SCHEMBL1760952 | 0.82 | LPL (0.49) | ALDH1A1CCR3CCR5SLC6A2SLC6A4 | |
| SCHEMBL3544423 | 0.78 | ALDH1A1 (0.43) | ALDH1A1TP53CYP3A4CCR3 | |
| SCHEMBL3171393 | 0.78 | ALDH1A1 (0.48) | ALDH1A1GMNNTP53CYP3A4ALOX15 | |
| SCHEMBL2930984 | 0.77 | TACR3 (0.57) | ALDH1A1TACR3SPRADAMTS5CCR3 | |
| SCHEMBL5224982 | 0.76 | S1PR5 (0.37) | ALDH1A1GMNNTP53CYP3A4ALOX15 | |
| SCHEMBL3546582 | 0.75 | NPC1 (0.46) | TP53NFKB1PROKR1 | |
| SCHEMBL11339489 | 0.73 | ALDH1A1 (0.55) | ALDH1A1SLC6A2SLC6A3FPR2PROKR1 | |
| SCHEMBL4959434 | 0.73 | ALDH1A1 (0.59) | ALDH1A1SPRADAMTS5CCR3 | |
| SCHEMBL1812750 | 0.72 | SLC2A1 (0.48) | ALDH1A1CCR3CCR5SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947692-B2 | Substituted thiazolo[5,4-d]pyrimidine urea derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-7666888-B2 | Substituted azole aromatic heterocycles as inhibitors of 11β-HSD-1 | AMGEN INC. (US) | 2010-02-23 | — | — | US | disclosed |
| EP-2051977-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1 | Amgen Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008011453-A2 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1 | AMGEN INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | AMGEN INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
| EP-1778675-A1 | CHIRAL PYRROLIDINE DERIVATIVES, AND METHODS FOR PREPARING COMPOUNDS THEREOF | Cylene Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006015150-A1 | CHIRAL PYRROLIDINE DERIVATIVES, AND METHODS FOR PREPARING COMPOUNDS THEREOF | CYLENE PHARMACEUTICALS (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025468-A1 | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof | CYLENE PHARMACEUTICALS | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021022-A1 | SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF 11BETA-HSD-1 | HSD17B1, HSD11B1, HSD17B11 | ALDH1A1 86/4885TACR3 3475/4885GMNN 4663/4885 |
| US-20060025468-A1 | Chiral pyrrolidine derivatives, and methods for preparing compounds thereof | PIN1, HPD, DHPS | ALDH1A1 1117/4885TACR3 1602/4885GMNN 655/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | ALDH1A1 676/4885TACR3 1336/4885GMNN 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.